21 August 2017
News and Views
Links and Services
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease, reports September's Alimentary Pharmacology & Therapeutics.
Adalimumab is an effective treatment for Crohn's disease (CD).
Email this page to a colleague
Whole-genome sequencing in primary care
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors